TransCon: Expanded Access Program of Palopegteriparatide in Patients with Hypoparathyroidism

Grants and Contracts Details

StatusActive
Effective start/end date9/25/249/25/26

Funding

  • Ascendis Pharma Bone Diseases AS: $2.00